Septerna Inc. (SEPN)
6.12
-0.25 (-3.92%)
At close: Mar 25, 2025, 3:59 PM
6.04
-1.17%
Pre-market: Mar 26, 2025, 07:01 AM EDT
-3.92% (1D)
| Bid | 5.69 |
| Market Cap | 271.52M |
| Revenue (ttm) | 345.68K |
| Net Income (ttm) | 3.62M |
| EPS (ttm) | -0.47 |
| PE Ratio (ttm) | -13.01 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.39 |
| Volume | 181,481 |
| Avg. Volume (20D) | 514,274 |
| Open | 6.38 |
| Previous Close | 6.37 |
| Day's Range | 6.08 - 6.43 |
| 52-Week Range | 4.17 - 28.99 |
| Beta | 4.26 |
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Prog...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 73
Stock Exchange NASDAQ
Ticker Symbol SEPN
Website https://septerna.com
Analyst Forecast
According to 4 analyst ratings, the average rating for SEPN stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 521.42% from the latest price.
Stock Forecasts1 month ago
-46.99%
Septerna shares are trading lower after the compan...
Unlock content with
Pro Subscription
